Catalysts / PRQR
Upcoming FDA decisions and readouts we track for ProQR Therapeutics, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for ProQR Therapeutics (PRQR, listed on Nasdaq). It concerns AX-0811 (Axiomer RNA-editing programme (first AI-discovered candidate)).
First on the list: the Phase 1 readout for AX-0811 (Axiomer RNA-editing programme (first AI-discovered candidate)), guided by the company to Early Jan 2027.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 07 Oct 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| ProQR Therapeutics PRQR · Nasdaq | AX-0811 | Axiomer RNA-editing programme (first AI-discovered candidate) | Early Jan 2027 company guidance |
Phase 1 readout | Verified | 6-K exhibit 99.1 ↗ | Yes |
FreeBioList